HAO News & Events

Haoxi Health Technology (HAO) and Eaglepoint AI, a subsidiary of Global Mofy AI Limited (GMM), jointly announced the signing of a three-year strategic cooperation agreement. The two parties will jointly commit R&D, data, and channel resources to launch an AI health management platform in China. Haoxi Health believes that this partnership marks its's exploration of potential opportunities in the AI-enabled healthcare sector. This collaboration also represents the first time that Eaglepoint AI has deployed its Aquila data engine and multimodal model evaluation system in a high-growth health management scenario.

Haoxi Health Technology announced that Beijing Haoxi Digital Technology has launched its customized livestreaming agency strategy and is progressing partnership discussions on personalized livestreaming agency services with several long-term clients of medical aesthetics. Driven by the growing demand for personalized and high-quality services in the healthcare and medical aesthetics sectors, and in response to evolving macro-consumption trends, Haoxi Beijing has officially launched its livestreaming agency services. This offering comes after the Company's establishment of a stable advertising delivery model built on long-term client servicing experience. The new service covers a full-cycle, closed-loop approach-from pre-campaign planning and livestream initiation to post-campaign analysis-tailored especially for the booming "light medical aesthetics" segment, including laser and injection-based treatments. It is designed to integrate evolving consumer behaviors with platform-specific operational strategies.

Haoxi Health Technology received a formal notification from the Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires the Company's Class A ordinary shares, par value $0.0025 each to maintain a minimum bid price of $1.00 per share. The Nasdaq staff made this determination of compliance after the closing bid price of the Company's Ordinary Shares has been at $1.00 per share or greater for the last 10 consecutive business days from January 27, 2025, to February 7, 2025. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and this bid price deficiency matter is now closed.

Haoxi Health Technology has resolved to effect a reverse share split of the Company's ordinary shares, with the split ratio set at 1-for-25. The Reverse Share Split was approved by the Company's shareholders at an annual general meeting of shareholders held on January 10, 2025. The Company's Class A ordinary shares will begin trading on an adjusted basis on the Nasdaq Capital Market, reflecting the Reverse Share Split, when the market opens on January 27, 2025, under the existing ticker symbol "HAO." The new CUSIP number for the Company's Class A ordinary shares will be G4290F118. Upon the effectiveness of the Reverse Share Split, every twenty-five shares of the Company's issued and outstanding Class A ordinary shares as of the effective date will automatically be combined into one Class A ordinary share, and every twenty-five shares of the Company's issued and outstanding Class B ordinary shares as of the effective date will automatically be combined into one Class B ordinary share. This adjustment will reduce the total number of outstanding Class A ordinary shares of the Company from approximately 53.29M to approximately 2.13M, and the total number of outstanding Class B ordinary shares of the Company from approximately 17.27M to approximately 0.69M. In conjunction with the Reverse Share Split, the Company also amended its Articles and Memorandum of Association to proportionately reduce the number of authorized shares for issuance and to adjust the par value of the post-reverse share split ordinary shares to $0.0025 per share.